|
시장보고서
상품코드
2039039
알파-1 안티트립신 결핍증 보충요법 시장 : 약제 유형별, 투여 경로별, 유통 채널별, 지역별Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, By Drug, By Route of Administration, By Distribution Channel, By Geography |
||||||
알파-1 안티트립신 결핍증 보충요법 시장은 2026년에 18억 7,820만 달러로 추정되며, 2033년까지 24억 6,190만 달러에 이를 것으로 예상되고 있습니다. 또한 2026-2033년 CAGR은 3.94%를 보일 전망입니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2025년 | 시장 규모(2026년) | 18억 7,820만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR | 3.94% | 예측 금액(2033년) | 24억 6,190만 달러 |
알파-1 안티트립신 결핍증은 α-1 항트립신 단백질의 수치가 부족해지는 유전성 질환입니다. 이 결핍은 폐와 간에 점진적인 손상을 일으켜 이들 장기의 기능 장애로 이어집니다. 이 질환은 전 세계적으로 약 2,000명에서 5,000명당 1명꼴로 발병합니다. 일반적으로 폐기종, 만성폐쇄성폐질환(COPD), 간질환의 발병과 관련이 있습니다. AATD 관리의 주요 치료법은 항프로테아제 활성을 증가시켜 폐를 보호하는 것을 목표로 하는 보충요법이 사용됩니다.
이 요법은 단백질 부족을 보충하고 질병의 진행을 늦추기 위해 사용됩니다. 세계 α-1 항트립신 결핍증 치료제 시장에는 주 1회 투여, 장기 투여 등 다양한 제제 외에도 새로운 바이오시밀러, 약물 투여법 등 다양한 제품이 존재합니다. 진단이 잘 이루어지지 않는 이 질환에 대한 인식이 높아지고 진단을 위한 새로운 접근법이 개발되면서 전 세계 α-1 항트립신 결핍증 치료제 시장의 성장에 기여하고 있습니다.
시장 역학
세계 α-1 항트립신 결핍증 치료제 시장은 빠르게 성장하고 있습니다. 이러한 성장은 주로 이 질환에 대한 인식이 높아짐에 따라 주도되고 있습니다. 또한, 스크리닝 및 유전자 검사를 포함한 진단 방법의 발전으로 더 많은 환자를 식별하는 과정이 간소화되었습니다. COPD 및 폐기종과 같은 호흡기 질환의 유병률 증가도 이러한 질환을 가진 더 많은 환자들이 진단을 받고 치료를 받으면서 시장을 주도하는 데 중요한 역할을 하고 있습니다.
그러나 이 시장에는 몇 가지 장벽이 존재합니다. 그 중 하나는 보충요법에 소요되는 고가의 비용입니다. 환자 1인당 연간 10만 달러가 훨씬 넘는 비용이 들기 때문에 이 치료법을 널리 제공하기가 어려워 의료기관에 부담을 주고 있습니다. 또한, 혈장을 사용하는 복잡한 제조 공정, 정부 규제, 환자 수가 적다는 점도 이 시장이 직면한 또 다른 과제입니다. 이러한 장애물은 시장 성장을 저해하는 요인으로 작용하고 있으며, 재조합 의약품 및 바이오시밀러 개발, 피하 투여와 같은 더 나은 투여 방법에는 많은 기회가 존재합니다.
본 보고서의 주요 특징
- 이 보고서는 각 부문의 잠재적 수익 기회를 밝히고 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한, 시장 촉진 및 억제요인 및 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략 등에 대한 중요한 고찰을 제공합니다.
- 세계 α-1 항트립신 결핍증 치료제 시장의 주요 기업 프로파일을 기업 개요, 제품 포트폴리오, 주요 특징, 재무 성과, 전략 등 다양한 매개 변수를 기반으로 정리했습니다.
- 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형 업데이트, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- '세계 알파-1 항트립신 결핍증 치료제 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 α-1 항트립신 결핍증 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 분석 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의알파-1 안티트립신 결핍증 보충요법 시장 : 약제 유형별(2021년-2033년)
제5장 세계의알파-1 안티트립신 결핍증 보충요법 시장 : 투여 경로별(2021년-2033년)
제6장 세계의알파-1 안티트립신 결핍증 보충요법 시장 : 유통 채널별(2021년-2033년)
제7장 세계의알파-1 안티트립신 결핍증 보충요법 시장 : 지역별(2021년-2033년)
제8장 경쟁 구도
제9장 애널리스트의 제안
제10장 참고 문헌이 및 분석 방법
LSH 26.06.04Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market is estimated to be valued at USD 1,878.2 Mn in 2026 and is expected to reach USD 2,461.9 Mn by 2033, growing at a compound annual growth rate (CAGR) of 3.94% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1,878.2 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 3.94% | 2033 Value Projection: | USD 2,461.9 Mn |
Alpha-1 Antitrypsin Deficiency (AATD) is a genetic disorder that results in insufficient levels of alpha-1 antitrypsin protein. This deficiency leads to lung and liver dysfunction because it causes progressive damage to these organs. This health condition affects about one person out of 2,000 to 5,000 worldwide. It is usually associated with the development of emphysema, chronic obstructive pulmonary disease (COPD), and liver issues. Augmentation therapy is used as the key treatment in the management of AATD in order to provide protection to the lungs via increasing anti-protease activity.
It is used to compensate for the insufficient levels of protein and slow down the progression of disease. There is a wide variety of products in the global Alpha-1 antitrypsin deficiency augmentation therapy market including different formulations like weekly or extended administration, as well as new biosimilars and drug administration methods. The growing awareness regarding the existence of this underdiagnosed condition and the development of new approaches to its diagnosis contribute to the growth of the global Alpha-1 antitrypsin deficiency augmentation therapy market.
Market Dynamics
The global Alpha-1 antitrypsin deficiency augmentation therapy market is expanding rapidly. This growth is largely driven by increased awareness of the condition. Furthermore, advancements in diagnostic methods, including screening and genetic testing, have simplified the process of identifying more individuals with the disease. The growing incidence of respiratory diseases, like COPD and emphysema, also plays an important role in driving the market, as more patients with these diseases are diagnosed and enrolled in treatments.
However, there are a number of hurdles in this market including the expensive cost involved in the use of augmentative therapies with a cost of well over USD 100,000 annually per patient, making it tough to make this treatment available and putting health care institutions under pressure. In addition, difficult production processes involving the use of plasma, government regulations, and low number of patients form other challenges faced by this market. Even though these obstacles pose a hurdle to growth in the market, there are many opportunities in the development of recombinant or biosimilars medications and better modes of administration such as subcutaneous.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global Alpha-1 antitrypsin deficiency augmentation therapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Grifols S.A., CSL Behring, Takeda Pharmaceutical Company Limited, Kamada Ltd., Baxter International Inc., LFB Biotechnologies, Pfizer Inc., AstraZeneca plc, Arrowhead Pharmaceuticals, Inc., and Vertex Pharmaceuticals Incorporated
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global Alpha-1 antitrypsin deficiency augmentation therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Alpha-1 antitrypsin deficiency augmentation therapy market
Market Segmentation
- Drug Insights (Revenue, USD Mn, 2021 - 2033)
- Glassia
- Aralast NP
- Prolastin C
- Trypsone
- Zemaira
- Late Phase Drug
- Route of Administration Insights (Revenue, USD Mn, 2021 - 2033)
- Inhalational
- Injections
- Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Grifols S.A.
- CSL Behring
- Takeda Pharmaceutical Company Limited
- Kamada Ltd.
- Baxter International Inc.
- LFB Biotechnologies
- Pfizer Inc.
- AstraZeneca plc
- Arrowhead Pharmaceuticals, Inc.
- Vertex Pharmaceuticals Incorporated
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, By Drug
- Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, By Route of Administration
- Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, By Distribution Channel
- Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trends
4. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, By Drug, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Glassia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Aralast NP
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Prolastin C
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Trypsone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Zemaira
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Late Phase Drug
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
5. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, By Route of Administration, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Inhalational
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Injections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
6. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, By Distribution Channel, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
7. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, By Region, 2021 - 2033, Value (USD Mn)
- Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Grifols S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- CSL Behring
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Kamada Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Baxter International Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- LFB Biotechnologies
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Arrowhead Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Vertex Pharmaceuticals Incorporated
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us
